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Epithelialovariancancerremainsamajorwomen’shealthproblemduetoitshighlethality.Despitegreateﬀortstodevelopeﬀective
prevention and early detection strategies, most patients are still diagnosed at advanced stages of disease. This pattern of late
presentationhasresultedinsigniﬁcantchallengesintermsofdesigningeﬀectivetherapiestoachievelong-termcure.Onepotential
promising strategy is the application of targeted therapeutics that exploit a myriad of critical pathways involved in tumorigenesis
and metastasis. This review examines three of the most provocative targeted therapies with current or future applicability in
epithelial ovarian cancer.
1.Introduction
Ovarian cancer represents the sixth most common malig-
nancy as well as the seventh leading cause of cancer-related
death in women worldwide [1, 2]. In the USA, this neoplasm
ranks second among gynecologic cancers, yet it is by far the
most lethal one, accounting for more than 15,000 deaths
annually [3]. One of the major reasons underlying this
dismal prognosis is the fact that nearly 75% of cases are
diagnosed at an advanced stage (i.e., tumor already spread
beyond the ovary) [4, 5], despite great eﬀorts to develop
reliable screening and prevention strategies.
To date, advanced ovarian cancer management has pre-
dominantly consisted of surgery followed by chemotherapy
consisting of a combination of platinums and taxanes. More
recently, neoadjuvant chemotherapy, a therapeutic alter-
native traditionally reserved for those patients considered
poor candidates for upfront surgery, has emerged as a
potential ﬁrst-line option [6]. Even though up to 80% of
these patients will respond to initial treatment, most of
them will subsequently recur [7]. Chemotherapy success
rates after relapse range from 10% to 50%, depending on
whether the tumor is platinum sensitive or resistant (i.e.,
a progression-free interval (PFI) following platinum-based
ﬁrst-line therapy of more or less than 6 months, resp.).
Unfortunately, almost all responses are invariably transient.
Thus, the 5-year overall survival (OS) for late-stage disease is
approximately 45% [2].
Since “nonspeciﬁc” therapies, namely, surgery, radia-
tion, and conventional chemotherapy, have largely failed to
achieve cure in the majority of patients aﬀected by epithelial
ovarian cancer, investigators have focused on developing
novel treatment approaches. Many of these new strategies
are based upon an understanding of the critical molecules
and pathways speciﬁcally involved in tumorigenesis and
metastasis. This has led to the development of “targeted”
oncologic therapies that might be ultimately more eﬀective
and less toxic.
Although signiﬁcant overlap occurs, targeted therapies
can be broadly divided into two categories:
(i) thosefocusedoncellularmechanismsthataredisreg-
ulated in carcinogenesis,
(ii) those directed against the neoplasm’s microenviron-
ment, a tumor component lately recognized as highly
relevant in both cancer growth and dissemination.
The present article addresses targeted therapies currently
being employed or tested in epithelial ovarian cancer
(EOC). Since their number has become as numerous as the2 Journal of Oncology
myriad of critical pathways involved in ovarian neoplastic
transformation, this review will focus on three of the most
promising and/or well-studied targeted weapons in ovarian
cancer therapeutics to date, namely,
(i) antiangiogenesis compounds,
(ii) epidermal growth factor receptor (EGFR) antago-
nists,
(iii) poly (ADP) ribose polymerase (PARP) inhibitors.
2.MaterialsandMethods
A comprehensive literature search was conducted using
the following key terms: “ovarian cancer”, “targeted thera-
pies”, “antiangiogenesis”, “epidermal growth factor receptor
(EGFR) inhibitors”, and “poly (ADP) ribose polymerase
(PARP) inhibitors”. For this purpose, primary sources used
were PubMed and Cochrane Databases. Articles’ selection
waslimitedtothosewritteninEnglish,withoutrestrictionto
year of publication. The main analysis was focused on those
studies providing clinical evidence, although preclinical data
were included either when background information was
required or when clinical assays were absent. Highly valuable
references cited by primarily collected studies as well as
pivotalabstractspresentedatprominentoncologicmeetings,
such as the Society of Gynecologic Oncologists (SGO), the
American Society of Clinical Oncology (ASCO), the Euro-
pean Society of Gynaecological Oncology (ESGO), and the
International Gynecologic Cancer Society (IGCS), were also
assessed and their data incorporated whenever pertinent.
3. Antiangiogenesis
Angiogenesis (i.e., the formation of new blood vessels)
plays a critical role in cancer expansion and propagation.
While many tumors start as avascular nodules, early data
demonstrated that growth is impaired beyond 2mm3 unless
eﬀective neovascularization is established [8]. Hence, this
phenomenon appears to be a rate-limiting step in tumor
progression. Antiangiogenic therapies have been shown to
inhibit new blood vessels development, induce endothelial
cells apoptosis, and normalize vasculature [5].
Many components interact in this process, such as
proangiogenic factors, metalloproteinases, and endothelial
precursor cells. Among angiogenesis-promoting molecules,
the vascular endothelial growth factor (VEGF) is the most
sensitive and potent one, as well as the best characterized
[9]. It is overexpressed in many human tumors, including
ovarian cancer. In ovarian malignancies, high levels of VEGF
have been associated with poor prognostic features, such as
advanced stage, carcinomatosis, distant metastasis, as well
as a decreased survival [10]. Thus, the VEGF pathway has
become one of the most attractive research areas in EOC
therapeutics. Preclinical data from animal models showed
that VEGF blockade was associated with inhibition of ascites
formation and tumor growth [11].
Bevacizumab, a recombinant humanized monoclonal
antibody directed against VEGF-A, was the ﬁrst of these
agents to be evaluated in EOC. Case reports and small ser-
ies constituted the initial clinical evidence supporting its
therapeutic value, mainly in recurrent, heavily pretreated
patients [12, 13]. Based on these ﬁndings, two phase II tri-
als using single-agent bevacizumab in recurrent ovarian
cancer, predominantly platinum-resistant disease, were sub-
sequently conducted (Table 1)[ 14, 15]. Their results demon-
strated the following.
(a) An overall response rate (RR) was of 15%–21%.
Unfortunately, less than 5% were complete respon-
ders.
(b) One study showed that additionally 50% of patients
had stable disease.
(c) A 6-month progression-free survival (PFS) ranged
from 30% to 40%.
(d) Hypertension was the most common side eﬀect
documented, being usually well controlled with
standard antihypertensive medication. However, two
major complications emerged, gastrointestinal per-
foration and thromboembolic disease, both venous
and arterial, ranging from 0% to 11% and 3% to
7%,respectively.Indeed,oneofthestudies,Cannistra
et al. [15], carried out in heavily pretreated patients,
was prematurely closed due to the high incidence of
bowel perforation observed.
(e) Bevacizumab-related deaths were estimated in up to
7% of treated patients.
This drug has been and continues to be tested in com-
bination with chemotherapy, as a part of the ﬁrst line trea-
tmentinnewlydiagnosedEOCandrecurrentdisease.Table 1
both summarizes the most relevant past and ongoing trials
conducted in this setting.
Other anti-VEGF as well as non-VEGF mediated Antian-
giogenic drugs are currently in clinical development. Table 2
illustrates some of these initiatives.
In conclusion, to date antiangiogenesis appears as one
of the most promising targeted strategies explored in EOC.
Given the encouraging initial results, bevacizumab has ent-
ered phase III trial evaluation. Meanwhile, it is considered
a viable option in the recurrent setting. Appropiate beva-
cizumab dose (7.5 versus 15mg/kg) and the ability to com-
bine with other biologics require further study as well. Safety
issues must be considered when using this compound. Ade-
quate patient selection may potentially reduce the incidence
of serious adverse events by excluding those at a highest risk
for gastrointestinal perforation or a thromboembolic event.
Major risk factors for these two complications have been
described (Table 3), yet it should be noted that they still
require further validation.
4. EpidermalGrowth Factor (EGF)
Receptors Antagonists
The family of EGF receptors (EGFRs) is composed of 4
structurally similar receptors which exert a tyrosine kinase
function: ErbB1 (commonly referred to as epidermal growthJournal of Oncology 3
Table 1: Clinical trials testing Bevacizumab in EOC.
Type Study’s Scope and Population Intervention Outcomes or Planned
End Points
Published
Burger
(2007) [14] Phase II
CR: 3%
62 patients with persistent or recurrent Ov or PP
cancers
PR: 18%
SD: 52%
66% had received two prior chemotherapy
regimens
Single-agent Bevacizumab MPFS: 4.7
6-mon PFS: 40%
42% were platinum-resistant MOS: 17
GIP: 0%
TED: 0%
Cannistra (∗)
(2007) [15] Phase II
CR: 0%
44 patients with recurrent Ov or PP cancers PR: 16%
48% had received three prior chemotherapy
regimens Single-agent Bevacizumab SD: Not reported
MPFS: 4.4
84% were platinum-resistant MOS: 10.7
GIP: 11%
TED: 7%
Micha (2007)
[16] Phase II
CR:30%
Adjuvant treatment in front-line Carboplatin + Paclitaxel +
Bevacizumab
PR:50%
20 patients stage III Ov, PP, or FT cancers SD: 5%
85% optimally cytoreduced TED: 10% (∗∗)
GIP: 0%
Garcia (2008)
[17] Phase II
CR: 0%
PR: 24%
70 patients with recurrent Ov or PP cancers Metronomic
Cyclophosphamide +
Bevacizumab
SD: 63%
Median n
o of prior chemotherapy regimens: 2 MOS: 17
40% were platinum-resistant MPFS: 7
TED: 4%
GIP: 4%
Ongoing
TEACO Phase II
1-year PFS
Adjuvant treatment in front-line Oxaliplatin + Docetaxel +
Bevacizumab (both ﬁrst
line and maintenance)
Safety
Stage IB-IV Ov, PP, or FT cancers RR
Either optimally or suboptimally cytoreduced PFS
OS
GOG 218 Phase III
PFS (primary)
Adjuvant treatment in front-line Carboplatin + Paclitaxel
with or without
Bevacizumab, either
short-term or extended
(maintenance)
OS
Stage III-IV Ov or PP cancers RR
Either optimally or suboptimally cytoreduced Toxicity
QoL
Translational
objectives
ICON 7 Phase III
Adjuvant treatment in front-line PFS (primary)
High-risk early stage (I-IIA, clear cell or grade 3)
or advanced stage (IIB or greater), either
optimally or suboptimally cytoreduced Ov, PP, or
FT cancers
Carboplatin + Paclitaxel
with or without extended
Bevacizumab
QoL
Cost eﬀectiveness4 Journal of Oncology
Table 1: Continued.
Type Study’s Scope and Population Intervention Outcomes or Planned
End Points
GOG 213 Phase III Platinum-sensitive recurrent Ov, PP, or FT
cancers
Carboplatin + Taxane with
or without Bevacizumab
with or without Secondary
cytoreduction
OS (primary)
PFS
Toxicity
OCEANS
(AVF4095g)
Phase III Platinum-sensitive recurrent Ov, PP, or FT
cancers
Carboplatin + Gemcitabine
with or without both
short-and long-term
(manitenance)
Bevacizumab
PFS
OS
RR
Safety proﬁle of the
combination
Ov: Ovarian; PP: Primary peritoneal; FT: Fallopian Tube
RR: Response rate; CR: Complete response; PR: Partial response; SD: Stable disease
TED: Thromboembolic disease (either arterial or venous); GIP: Gastrointestinal perforation
M P F S :M e d i a np r o g r e s s i o n - f r e es u r v i v a l( m o n t h s ) ;M O S :M e d i a no v e r a l ls u r v i v a l( m o n t h s ) ;
QoL: Quality of life
(∗) Study stopped prematurely due to the high rate of severe complications (i.e., GIP)
(∗∗) TED cases were not directly attributed to bevacizumab.
factor receptor), ErbB2 (Her2/neu), ErbB3 (Her3), and
ErbB4 (Her4). Their activation triggers a cascade of events
ultimately resulting in cell proliferation and survival. Like
VEGF, EGFRs are frequently overexpressed and/or dysreg-
ulated in solid tumors. Ovarian cancer is not an exception,
with up to 70% of cases exhibiting this aberrant phenotype,
which has been linked to poor oncologic features and
outcomes [5, 7, 29].
These observations have suggested that EGFRs might
represent a viable target for novel therapies in EOC. While
blockade of these receptors can be achieved by several mech-
anisms, two of these have been most extensively explored:
(a) small molecules capable of inhibiting the tyrosine kinase
domain and (b) monoclonal antibodies directed against the
extracellular region.
Preliminary preclinical data demonstrated antitumoral
activity and a reversion of the chemoresistant phenotype
secondary to EGFR inhibition [30]. Nonetheless, and in
contrastwiththe promising resultsobtained withanti-VEGF
therapies, to date clinical trials with EGFR inhibitors alone
have produced disappointing results.
4.1.TyrosineKinaseInhibitors(TKIs). Geﬁtinibanderlotinib
are two of the main compounds in this category. Both are
orally administrated and relatively well tolerated [31], which
would represent a signiﬁcant advantage in terms of patients’
quality of life. Core ﬁndings from the most relevant trials
conducted on these agents can be summarized as follows
[32–38].
( a )A nR Ri nr e c u rr e n to v a ri a nc a n c e ri so fl e s st h a n1 0 %
along with stable disease in up to 44% of patients
when used as single agents.
(b) These results were improved either when geﬁtinib
was combined with standard chemotherapy or when
erlotinib was combined with bevacizumab. The com-
bination geﬁtinib-tamoxifen did not appear to add
any clinical beneﬁt.
(c) As a part of the ﬁrst-line treatment in conjunction
with a platinum and a taxane, either upfront or as
consolidation therapy, TKIs have yet to conﬁrm a
demonstrable survival advantage. The EORTC has
just ﬁnalized the recruitment of a phase III trial
exploring erlotinib as maintenance therapy in both
high-risk early-stage and advanced diseases.
(d) In terms of side eﬀects, the most frequently observed
were diarrhea (up to 30%, being the dose-limiting
toxicity), nauseas and vomiting (nearly 10%), and
an acne-like cutaneous rash (5%–15%), which inter-
estingly correlated positively with tumor response.
As expected, increased toxicity was seen when a
cytotoxic agent was coadministrated.
As noted above, the initial experience with these agents
has not revealed a deﬁnitive role in the treatment of
unselected EOC population, either in the ﬁrst-line or the
relapsed setting. However, a subgroup of patients showing
an increased likelihood to respond to these compounds has
been identiﬁed. In Schilder’s trial, published in 2005, clinical
outcomes correlated with EGFR status, with a signiﬁcantly
longer progression-free survival (PFS) as well as a trend
in improved overall survival (OS) among those who were
EGFR(+).Speciﬁcally,anenhancedresponsetogeﬁtinibwas
linked to the presence of an infrequent mutation aﬀecting
the catalytic domain of this receptor [32]. This relationship
closely resembles what previously has been described in lung
cancer [39, 40]. Thus, it has been suggested that prescreening
patients for speciﬁc active EGFR mutations could deﬁne the
population most likely to beneﬁt from this therapy. Further
investigation to validate this ﬁnding in EOC is warranted.
Novel EGFR inhibitors in development for EOC include
lapatinib, canertinib, PKI-166, and EKB-569. Until better
evidence supporting a relevant therapeutic value becomes
available, the role of TKIs in this neoplasm remains predom-
inately conﬁned to clinical trials.Journal of Oncology 5
Table 2: Examples of other promising Antiangiogenic agents in EOC.
Mechanism of action Current evidence
VEGF-mediated
Aﬂibercept
(VEGF-Trap)
Soluble receptor which binds VEGF-A
and-B as well as placenta-derived growth
factor (PlGF) 1 and 2
Preliminary results reported by a Phase II trial conducted in
recurrent setting showed similar results than bevacizumab,
with a remarkable less incidence of bowel perforation (1%)
[18]
A phase III trial is ongoing
Cediranib
Small molecule that inhibits the tyrosine
kinase domain of the VEFG receptor
(VEGFR)
Two phase II trials in relapsing EOC demonstrated a response
rate of nearly 20%, increasing up to 30% if disease stabiliza-
tion is considered [19, 20]
Other members of this family are sorafenib
and sunitinib
ICON 6, a phase III trial in recurrent platinum-sensitive
patients, is now testing this agent in combination with
carboplatin and paclitaxel
Sorafenib
Multitargeted TKI that inhibits raf kinase,
VEGFR-2, VEGFR-3, Flt-3, c-kit, and
platelet-derived growth factor receptor
(PDGFR)
Phase I trial reported that 50% of patients showed stable
disease [21]. Early data from a subsequent phase II study
testing the combination of sorafenib with gemcitabine in
recurrent EOC conﬁrmed encouraging activity, with an
overall response rate of 33% [22]
Several other phase II trials employing sorafenib either in
front-line, maintenance phase, or recurrent settings, alone
or in combination with standard chemotherapy or biologics
(e.g., bevacizumab) are underway
A randomized phase III trial is currently evaluating Sorafenib
as a maintenance therapy after ﬁrst-line treatment in EOC
Pazopanib Oral tyrosine kinase inhibitor that targets
VEGFR, PDGFR, and c-kit
Preliminary results of a phase II trial conducted in recurrent
EOC deﬁned by CA-125 elevation showed a biochemical
response of 47%, with stable disease observed in other 27%
[23]
A phase III trial is currently evaluating pazopanib as a
maintenance therapy after ﬁrst-line treatment in EOC
Non VEGF-
mediated
Vascular
disrupting
agents (VDAs)
Represent a new approach to deprive tumor
fromitsbloodsupply,bycausingthecollapse
of the established tumor vasculature. Their
main targets are the endothelial cells
Preclinical data indicate that these drugs can improve tumor
response to chemotherapy [24], radiation, and other Antian-
giogenic therapies
Examples include tubulin destabilizers and
ﬂavanoids, among others
Zweifel and coworkers presented recently the ﬁnal results of
a phase II trial employing Fosbretabulin (a tubulin binder)
along with carboplatin and paclitaxel in platinum-resistant
EOC, revealing a response rate of 32% [25]
Table 3: Major risks factors potentially associated with bevacizum-
ab-induced arterial thrombo-embolism and gastrointestinal perfo-
ration.
1- Arterial Thromboembolic Events (ATEs) [26]
–Age ≥65 years
–Prior history of ATE
2- Gastrointestinal Perforation [27, 28]
–Multiple prior chemotherapy regimens (heavily
pretreated patients)
–Large intraabdominal tumor burden
–Neoplastic bowel involvement
–Clinical evidence of partial obstruction
4.2. Monoclonal Antibodies. Various humanized antibodies
againsttheextracellularregionofEGFRhavebeenthoughtto
be potentially eﬀective in EOC. Nonetheless, similar to what
has occurred with TKIs, the theory has not been conﬁrmed
clinically.Probablythemostemblematicexampleillustrating
this unfulﬁlled potential has been trastuzumab. Multiple
initial studies conﬁrmed that Her-2/neu overexpression
was associated with an adverse prognosis of patients with
epithelial ovarian cancer [41, 42]. Trastuzumab, a selective
Her-2/neuinhibitorapprovedforthetreatmentofErbB2(+)
metastatic breast cancer, was proposed to have antitumoral
activity comensurate with that observed in breast cancer.
Further clinical evidence in a large GOG trial, however,
demonstrated a response rate of only 7%, with disease6 Journal of Oncology
Table 4: Other Anti-EGFR antibodies explored in EOC.
Antibody Target Clinical data available
Cetuximab ErbB1
Three phase II trials (one as a component of the ﬁrst-line treatment and two performed in
recurrence), alone or in combination with conventional cytotoxic therapy, have evidenced null
or only modest impact of cetuximab in the management of EOC [44–46]
Matuzumab ErbB1 One phase II study conducted in platinum-resistant, EGFR (+) population, concluded that
matuzumab was well-tolerated, but lacked signiﬁcant clinical activity [47]
Pertuzumab Her2/neu
One phase II trial involving advanced, refractory EOC patients has been conducted using this
agent. Like matuzumab, pertuzumab was associated with a poor response rate (approximately
4%) [48]
stabilization in other 39% of ErbB 2(+) recurrent ovarian
cancer patients [43].
Results obtained with other monoclonal antibodies,
alone or in combination with standard chemotherapy, are
outlined in Table 4.
5.PARPInhibitors
Approximately 10% of ovarian cancers are considered hered-
itary. Germline mutations aﬀecting two genes, BRCA1 and
BRCA2, account for the vast majority of these cases. The
lifetime risk of developing an epithelial ovarian carcinoma
among women who carry these genetic defects has been
e s t i m a t e dt ob eu pt o6 0 %[ 49]. The proteins encoded by
these tumor suppressor genes participate in multiple cellular
processes, including transcription, cell cycle regulation, and
repair of DNA double-strand breaks [50]. When inactived,
chromosome instability occurs, an event potentially facilitat-
ing carcinogenesis.
Many other DNA-repair mechanisms are generally avail-
able within the normal cell. The base-excision repair (BER)
complex constitutes one of them. The enzyme poly (ADP)
ribose polymerase (PARP) is a key component of this
pathway. Its scope is restricted to single-strand defects.
Accordingly, its malfunction theoretically should not aﬀect
double-strand repair; however, a persistent single-strand
defect may ultimately result in DNA replication interruption
or a double-strand break [51]. When this occurs in a cell
that is already unable to repair DNA damage , as the case
for BRCA-defective cells, cell cycle arrest or death occurs.
This observation, known as synthetic lethality [52], supports
the contention that PARP blockade would be therapeutically
eﬀective in hereditary EOC. This premise was initially
conﬁrmed in preclinical studies demonstrating a highly
increased sensitivity to PARP inhibition among BRCA-
deﬁcient cells, with a subsequent decreased cell survival,
compared to those heterozygous or BRCA wild-type cells
[53, 54].
Clinical studies exploiting this approach have been
recently conducted in multiple human solid tumors. Initial
trialsusedtheseagentsprimarilyaschemosensitizers,mainly
in association with methylating compounds [55]. However,
with the demonstration of BRCA speciﬁc sensitivity, single-
agent inhibitors were assessed. Recently, ﬁnal results of the
ﬁrstphaseItrialevaluatingOlaparib,anorallyadministrated
PARP inhibitor, in BRCA-defective malignancies, including
ovarian cancer, showed a low toxicity along with a response
or disease stabilization rate of 63% [56]. Multiple PARP
inhibitors are currently being examined in phase II trials.
Of interest, Audeh et al. lately reported the interim analysis
of a phase II study employing Olaparib in BRCA-deﬁcient
advanced ovarian cancer [57]. Overall 57% of patients
demonstrated response to PARP inhibition, using either
RECIST or CA-125 criteria. Potential use of PARP inhibitors
as chemoprophylactics in BRCA mutation carriers [58]a n d
fortreatingsporadicovariancancers[49]hasbeenpr oposed,
as well.
A potential barrier to PARP inhibitors use has been the
recently described emergence of resistance by reversal of the
BRCA-deﬁcient phenotype [59]. The clinical implications of
this phenomenon require further clariﬁcation.
6. Conclusions and FutureOverview
Women with epithelial ovarian cancer are living for longer
periods of time than ever before. Development of novel
chemotherapeutics has in part contributed to this improved
outcome. However, a signiﬁcant proportion of aﬀected
patientsstillsuccumbstothisdiﬃcultdisease.Thus,progress
is still needed. To this end, targeted therapies appear to be a
promising platform for clinical development.
Many cellular pathways have been implicated in ovarian
carcinogenesis, and exploitation of these perturbations criti-
cal in forming or maintaining the malignant phenotype has
yieldedanumberofpromisingcompounds.However,todate
only Antiangiogenic agents have reached clinical relevance in
EOC management. New therapeutic tools showing promis-
ing results, such as PARP inhibitors that exploit the abnor-
mality responsible for the initial neoplastic transformation,
have demonstrated encouraging clinical potential.
Some relevant lessons learned in targeted therapy devel-
opment thus far include [7] the following.
(i) The mere presence of a particular molecule or path-
way dysregulated in a particular tumor does not
guarantee that its inactivation will have therapeutic
beneﬁt.
(ii) Response does not always translate into prolonged
survival, symptom relief, or other valuable clinical
endpoints. Conversely, there may be signiﬁcant imp-
rovements in time-to-event endpoints such as time-
to-progression or PFS, and yet objective responsesJournal of Oncology 7
may be rare. Thus diﬀerent clinical parameters may
be neccesary for eﬃcacy assessment of targeted
agents.
(iii) Given the multiplicity and redundancy of aberrant
pathways involved in ovarian cancer, it is unlikely
that inhibition of a single cascade will be highly
eﬀective. Thus agents that act upon multiple levels
or interconnected pathways simultaneously appear
potentially more promising.
The future of cancer therapeutics will likely include
tailored, individualized treatments, designed on the basis
of an even deeper understanding of the critical alterations
in ovarian carcinogenesis. Gene expression proﬁles have
established that this neoplasia is far from being a uniform
disease [60]. Thus, genotype-directed and pharmacoge-
nomic therapies emerge as the next frontier for fruitful
exploration and novel drug development.
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